Trevi Therapeutics (TRVI) Shares Outstanding (Weighted Average) (2018 - 2026)

Trevi Therapeutics has reported Shares Outstanding (Weighted Average) for 9 years, with the latest figure at $145.6 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 23.79% year-over-year to $145.6 million; the trailing twelve-month figure through Mar 2026 stood at $145.6 million (up 23.79% YoY), and the FY2025 full-year result was $134.7 million, up 32.14% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $145.6 million, up from $134.7 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $145.6 million in Q1 2026, with the low at $30.8 million in Q1 2022.
• Average Shares Outstanding (Weighted Average) over 5 years is $96.8 million, with a median of $99.5 million recorded in 2024.
• Year-over-year, Shares Outstanding (Weighted Average) jumped 220.1% in 2023 and rose 0.92% in 2024.
• Tracing TRVI's Shares Outstanding (Weighted Average) over 5 years: stood at $64.5 million in 2022, then jumped by 53.44% to $99.0 million in 2023, then grew by 2.97% to $102.0 million in 2024, then surged by 32.14% to $134.7 million in 2025, then gained by 8.05% to $145.6 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $145.6 million (Q1 2026), $134.7 million (Q4 2025), and $131.1 million (Q3 2025), per Business Quant data.

Peer Comparison